FDA Warnings About Counterfeit Semaglutide Pens: What's Been Flagged
The FDA has issued advisories about counterfeit semaglutide entering the U.S. supply chain through channels outside licensed pharmacies.
By the GLP Semaglutide editorial team · Last updated July 15, 2026
The FDA has published consumer and pharmacy-facing advisories about counterfeit semaglutide products, including pens and vials found to contain different or unverified active ingredients, or that entered the supply chain outside legitimate distribution channels.
How counterfeits have been identified
In past advisories, counterfeit products have been identified through mismatched needle attachments, incorrect labeling, and reports of adverse events that prompted lab testing revealing the product didn't match its labeling.
Reducing exposure to counterfeit risk
Sourcing medication through a licensed pharmacy against a valid prescription substantially reduces counterfeit exposure compared with unverified online sellers. Patients who suspect a counterfeit product can report it to the FDA's MedWatch program.
Primary sources